Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection
Primary Purpose
Venous Thromboembolism
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
blood tests
Sponsored by
About this trial
This is an interventional diagnostic trial for Venous Thromboembolism
Eligibility Criteria
Inclusion Criteria:
- subjects who are having primary, open resection surgery of gastrointestinal or bladder cancer
Exclusion Criteria:
- currently receiving anticoagulation therapy
- pregnant
Sites / Locations
- University of Colorado Hospital
Arms of the Study
Arm 1
Arm Type
No Intervention
Arm Label
diagnostic blood tests
Arm Description
We are using 2 standard approved blood tests that may be useful in predicting who may develop a venous thromboembolism after cancer surgery.
Outcomes
Primary Outcome Measures
Venous thromboembolism free survival after surgery for gastrointestinal or urologic cancer
Secondary Outcome Measures
Full Information
NCT ID
NCT01608919
First Posted
May 29, 2012
Last Updated
August 7, 2015
Sponsor
University of Colorado, Denver
1. Study Identification
Unique Protocol Identification Number
NCT01608919
Brief Title
Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection
Official Title
Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2015
Overall Recruitment Status
Terminated
Why Stopped
Sara Cheng, MD has left the University of Colorado and we have closed this study.
Study Start Date
November 2012 (undefined)
Primary Completion Date
January 2014 (Actual)
Study Completion Date
January 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study plans to learn more about the role of 2 blood tests in predicting who might develop a blood clot in their arm or leg after major surgery. The investigators know that patients who have cancer and major surgery have a higher than normal risk of getting blood clots in the veins of their arms or legs. This can be very dangerous because the clot can move into your lungs.
Detailed Description
Venous Thromboembolism (VTE) after cancer surgery hospitalization is the most common cause of death at 30 days after cancer surgery, and is a significant source of patient morbidity and health care cost. Pharmacoprophylaxis has proven efficacy in preventing post-discharge VTE in surgical cancer patients, but perceived risks and costs pose barriers to widespread adoption by clinicians. Risk stratification of this patient population is necessary to allow appropriate prescription of prophylaxis to the highest risk patients. Can the investigators develop a risk stratification model that includes a readily available laboratory test, the thromboelastogram with or without platelet mapping?
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Venous Thromboembolism
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
4 (Actual)
8. Arms, Groups, and Interventions
Arm Title
diagnostic blood tests
Arm Type
No Intervention
Arm Description
We are using 2 standard approved blood tests that may be useful in predicting who may develop a venous thromboembolism after cancer surgery.
Intervention Type
Other
Intervention Name(s)
blood tests
Intervention Description
thromboelastogram platelet mapping
Primary Outcome Measure Information:
Title
Venous thromboembolism free survival after surgery for gastrointestinal or urologic cancer
Time Frame
3 months post-discharge from hospital
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
subjects who are having primary, open resection surgery of gastrointestinal or bladder cancer
Exclusion Criteria:
currently receiving anticoagulation therapy
pregnant
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sara Cheng, MD, PhD
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Hospital
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Predictive Value of Whole Blood Coagulation Parameters for Post-discharge Venous Thromboembolism After Cancer Resection
We'll reach out to this number within 24 hrs